Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Buy Or Sell MetLife Stock Before Earnings?

Published 07/30/2017, 04:50 AM
US500
-
MET
-

MetLife (NYSE: NYSE:MET) is a $60 billion company today. Investors that bought shares one year ago are sitting on a 32.67% total return. That's above the S&P 500's return of 16.31%.

MetLife stock is beating the market, and it reports earnings next week. But does that make it a good buy today? To answer this question, we've turned to the Investment U Stock Grader. Our Research Team built this system to diagnose the financial health of a company.

Our system looks at six key metrics...

Earnings-per-Share (EPS) Growth: MetLife reported a recent EPS growth rate of -62.31%. That's below the insurance industry average of 51.68%. That's not a good sign. We like to see companies that have higher earnings growth.

Price-to-Earnings (P/E): The average price-to-earnings ratio of the insurance industry is 17.15. And MetLife's ratio comes in at 11.99. It's trading at a better value than many of its competitors.

Debt-to-Equity : The debt-to-equity ratio for MetLife stock is 35.24. That's below the insurance industry average of 53.65. The company is less leveraged.

Free Cash Flow per Share Growth : MetLife's FCF has been higher than that of its competitors over the last year. That's good for investors. In general, if a company is growing its FCF, it will be able to pay down debt, buy back stock, pay out more in dividends and/or invest money back into the business to help boost growth. It's one of our most important fundamental factors.

Profit Margins : The profit margin of MetLife comes in at 5.08% today. And generally, the higher, the better. We also like to see this margin above that of its competitors. MetLife's profit margin is below the insurance average of 9.2%. So that's a negative indicator for investors.

Return on Equity : Return on equity tells us how much profit a company produces with the money shareholders invest. The ROE for MetLife is -0.97%, and that's below its industry average ROE of 10.28%.

MetLife stock passes three of our six key metrics today. That's why our Investment U Stock Grader rates it as a Hold.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.